A study of SGT-001 for the treatment Duchenne muscular dystrophy (DMD).
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2017
At a glance
- Drugs SGT 001 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 30 Mar 2017 According to a Solid Biosciences media release, the company anticipates to initiate this study in the second half of 2017.
- 10 Nov 2016 New trial record